Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis
Open Access
- 1 March 2019
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , e108-e111
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustineBlood, 2018
- Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over TimeJournal of Clinical Oncology, 2018
- Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathBlood, 2017
- European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M–Related Light Chain AmyloidosisJournal of Clinical Oncology, 2016
- Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyJournal of Clinical Oncology, 2015
- Clinical presentation and treatment responses in IgM-related AL amyloidosisAmyloid, 2015
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival OutcomesJournal of Clinical Oncology, 2012
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain MeasurementsJournal of Clinical Oncology, 2012
- IgM Amyloidosis: Clinical Features in Therapeutic OutcomesClinical Lymphoma Myeloma and Leukemia, 2011
- Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and DexamethasoneClinical Lymphoma Myeloma and Leukemia, 2011